Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) subsidiary Bausch & Lomb said today it won FDA 510(k) clearance for its Stellaris Elite vision enhancement system. The system is a next-gen phacoemulsification cataract platform designed for cataract lens removal, and offers improved customization and precise aspiration control with predictive infusion management, Bausch & Lomb said. “We are pleased to continue […]
Optical/Ophthalmic
Defendants move for acquittal in Abbott-Advanced Medical Optics insider trading case
The defendants in an insider trading case yesterday asked a federal judge in California to acquit them of all charges, arguing that the government failed to show any evidence that they traded on inside dope about Abbott‘s (NYSE:ABT) $2.8 billion acquisition of Advanced Medical Optics in 2009. Federal prosecutors in 2014 accused ex-Advanced Medical Optics chief James Mazzo of tipping […]
Chinese backers put $18m into Bionic Vision Technologies
A pair of Chinese backers put $18 million into Bionic Vision Technologies and its retinal implant for blindness, the Australian company said today. Hong Kong-based China Huarong International Holdings and State Path Capital ponied up A$23.5 million, BVT said, noting that it plans to use the cash to build devices and launch clinical trials in retinitis pigmentosa, based […]
Clearside inks clinical development deal with EyeKor
Clearside Biomedical (NSDQ:CLSD) said today that it landed a deal with EyeKor Inc. to support its clinical trials. The companies did not disclose any financial details of the agreement. Clearside is conducting a Phase III trial of suprachoroidally administered CLS-TA, its suspension formulation of triamcinolone acetonide, in patients with macular edema associated with non-infectious uveitis. The […]
Aura Biosciences wins fast track designation for light-activated nanoparticle therapy
Aura Biosciences said today that it enrolled and dosed the 1st patient in the Phase Ib trial of its light-activated AU-011 viral nanoparticle conjugate therapy for the treatment of ocular melanoma. The company also said that the FDA granted fast track designation to its targeted treatment, which will give priority review for the company’s New Drug […]
6 visual impairment breakthroughs you need to know
About 285 million people have some form of visual impairment in the world, according to the World Health Organization. Of that number, 39 million are considered blind, and 246 million have low vision. Three-fifths of all vision impairment can be prevented or cured. Uncorrected refractive errors are one of the main causes of vision impairment in […]
Novaliq, AFT Pharmaceuticals ink licensing deal for NovaTears dry eye therapy
Ocular therapeutics company Novaliq said today that it inked a strategic licensing agreement with AFT Pharmaceuticals for the commercialization of its dry eye therapy, NovaTears, in Australia and New Zealand. NovaTears is the Germany-based company’s 1st commercially available product indicated for the treatment of evaporative dry eye diseases. Get the full story at our sister site, Drug […]
Opthea gets positive feedback from European regulatory groups for wet-AMD injection
Opthea (ASX:OPT) said today that it received positive feedback from meetings with the U.K.’s Medicines and Healthcare Products Regulatory Agency and Sweden’s Medical Products Agency over its OPT-302 therapy for the treatment of wet age-related macular degeneration. The Australia-based company’s OPT-302 therapy consists of a soluble form of vascular endothelial growth factor receptor 3 that […]
Study: Vision loss treatment linked to higher risk of glaucoma surgery
Researchers from the University of British Columbia found that patients with age-related macular degeneration who had at least 7 eye injections per year had a heightened risk of having glaucoma surgery. The team’s findings were published this week in JAMA Ophthalmology. Patients with wet age-related macular degeneration and diabeteic macular edema, common causes of vision loss, are […]
Visioneering Technologies closes $26m IPO
Visioneering Technologies Inc said today it closed a $25.5 million (AUD $33.3 million) initial public offering in Australia, with funds slated to support its NaturalVue multifocal contact lenses. In the offering, the Alpharetta, Ga.-based company floated approximately 79.4 million shares of Class A common stock at 32¢ (AUD 42¢) per share, with strong support from Australian […]
Ocular touts patient experience data for Dextenza implant
Ocular Therapeutix (NSDQ:OCUL) touted data today from a patient experience study of its Dextenza post-surgical pain relief implant. The study was published in Patient Preference and Adherence. The Bedford, Mass.-based company’s hydrogel plug, inserted into a patient’s tear duct, is designed to deliver a sustained dose of dexamethasone over 4 weeks following ophthalmic surgery. After the […]